{"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"254"},{"groupId":"BG002","value":"257"},{"groupId":"BG003","value":"758"}],"units":"Participants"}],"groups":[{"description":"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"BG000","title":"Tandem Auto Transplant"},{"description":"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance\n\nlenalidomide, bortezomib and dexamethasone: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"BG001","title":"RVD Consolidation"},{"description":"Initial autologous transplant followed by lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"BG002","title":"Lenalidomide Maintenance"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"70","value":"56"},{"groupId":"BG001","lowerLimit":"20","upperLimit":"70","value":"57"},{"groupId":"BG002","lowerLimit":"30","upperLimit":"70","value":"56"},{"groupId":"BG003","lowerLimit":"20","upperLimit":"70","value":"56"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"304"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"161"},{"groupId":"BG003","value":"454"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"201"},{"groupId":"BG003","value":"571"}],"title":"Caucasian"},{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"130"}],"title":"African American"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"57"}],"title":"Multiple/Other/Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"172"},{"groupId":"BG003","value":"523"}],"title":"90 or Greater"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"85"},{"groupId":"BG003","value":"235"}],"title":"Less Than 90"}]}],"description":"KPS describes patient-perceived global quality of life and functioning on a scale of 0-100.\n\n100: No evidence of disease; 90: Normal activity. Minor signs or symptoms of disease; 80: Normal activity with effort. Some signs or symptoms of disease; 70: Cares for self. Unable to continue normal activity; 60: Needs occasional assistance, but cares for most personal needs; 50: Needs considerable assistance and medical care; 40: Disabled. Needs special care and assistance; 30: Severely disabled. Hospital admission indicated; 20: Very sick. Active supportive therapy needed; 10: Moribund; 0: Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Karnofsky Performance Score (KPS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"178"},{"groupId":"BG002","value":"182"},{"groupId":"BG003","value":"535"}],"title":"Standard"},{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"223"}],"title":"High"}]}],"description":"Participants on this study will be stratified for the purposes of statistical analysis into high-risk and standard risk-groups. High-risk multiple myeloma is defined by the presence of high beta-2 microglobulin (\\> 5.5mg/L) or the presence of cytogenetic abnormalities including t(4;14), t(14;20), t(14;16), deletion (17p) detected by FISH or standard cytogenetics, deletion 13 detected by standard cytogenetics only or aneuploidy. Participants without cytogenetic analysis available and beta-2 microglobulin ≤ 5.5mg/L or with deletion 13 detected by FISH will be classified as standard-risk disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Risk","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"143"},{"groupId":"BG003","value":"420"}],"title":"Bortezomib/Lenalidomide/Dexamethasone"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"108"}],"title":"Bortezomib/Cyclophosphamide/Dexamethasone"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"74"}],"title":"Lenalidomide/Dexamethasone"},{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"93"}],"title":"Bortezomib/Dexamethasone"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"58"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"title":"Unknown"}]}],"description":"Initial therapy administered for the treatment of multiple myeloma","paramType":"COUNT_OF_PARTICIPANTS","title":"Initial Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"14","value":"5"},{"groupId":"BG001","lowerLimit":"2","upperLimit":"12","value":"5"},{"groupId":"BG002","lowerLimit":"2","upperLimit":"12","value":"5"},{"groupId":"BG003","lowerLimit":"2","upperLimit":"14","value":"5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time from Initial Therapy to Enrollment","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"210"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"218"},{"groupId":"BG003","value":"641"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"104"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"title":"Unknown"}]}],"description":"Lines of therapy is defined as the number of different regimens received prior to study entry.","paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Lines of Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"70"}],"title":"Stringent Complete Response"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"65"}],"title":"Complete Response"},{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"73"}],"title":"Near Complete Response"},{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"148"}],"title":"Very Good Partial Response"},{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"123"},{"groupId":"BG003","value":"337"}],"title":"Partial Response"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"49"}],"title":"Stable Disease"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"}],"title":"Progression"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}],"title":"Not Evaluable"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status at Enrollment","unitOfMeasure":"Participants"}]}